Loading…
Innoviva, Inc. is projected to rise to $25.24 by 2027, a +13% move from its current price of $22.24. INVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $21.94 | $22.26 | $22.57 | +0.07% |
| Jul 15 | $21.83 | $22.27 | $22.72 | +0.14% |
| Jul 16 | $21.75 | $22.29 | $22.84 | +0.21% |
| Jul 17 | $21.68 | $22.30 | $22.94 | +0.28% |
| Jul 18 | $21.62 | $22.32 | $23.04 | +0.36% |
| Jul 19 | $21.57 | $22.34 | $23.12 | +0.43% |
| Jul 20 | $21.53 | $22.35 | $23.20 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.53 | $22.35 | $23.20 | +0.50% |
| Week 2 | $21.30 | $22.46 | $23.68 | +1.00% |
| Week 3 | $21.16 | $22.57 | $24.09 | +1.50% |
| Week 4 | $21.05 | $22.69 | $24.45 | +2.01% |
| Week 5 | $20.97 | $22.80 | $24.79 | +2.52% |
| Week 6 | $20.91 | $22.91 | $25.11 | +3.03% |
| Week 7 | $20.86 | $23.03 | $25.43 | +3.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
In addition, the company markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva, Inc. (INVA) is currently trading at $22.49 per share. Its market cap is $1.66B and its market rank is 2165. The stock trades within a 30-day price range of $20.76 to $24.37.
A major floor 9.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 6.3% above — a clean break opens room to run.
A major ceiling 11.1% above — clearing it would confirm fresh momentum.
Key INVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.19 | Buy | $22.28 | Sell |
| MA 10 | $22.46 | Sell | $22.40 | Sell |
| MA 20 | $22.66 | Sell | $22.50 | Sell |
| MA 50 | $22.50 | Sell | $22.55 | Sell |
| MA 100 | $22.78 | Sell | $22.32 | Sell |
| MA 200 | $21.25 | Buy | $21.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.59 | Neutral |
| Stoch RSI (14) | 24.83 | Neutral |
| CCI (20) | -67.28 | Neutral |
| Williams %R (14) | -76.92 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -5.56 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 23.08 | Neutral |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 44.77 | Neutral |
| Momentum (10) | -1.11 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 22.23 | Buy |
| ADX (14) | 10.76 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bullish. RSI14 is 50, with the 50-day simple moving average at $22.80 and the 200-day simple moving average at $21.06. Support is seen at $21.35 and resistance at $23.14, framing a near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.31 | $22.24 | $29.74 | 0% | Neutral | |
| $20.67 | $25.24 | $32.22 | +13% | Neutral | |
| $24.83 | $30.89 | $40.50 | +39% | Bullish | |
| $30.32 | $38.30 | $51.28 | +72% | Bullish | |
| $31.46 | $40.27 | $54.90 | +81% | Bullish | |
| $34.79 | $45.09 | $62.43 | +103% | Bullish | |
| $37.10 | $48.62 | $68.28 | +119% | Bullish | |
| $37.39 | $49.51 | $70.43 | +123% | Bullish | |
| $41.00 | $54.84 | $78.94 | +147% | Bullish | |
| $46.32 | $62.53 | $91.02 | +181% | Bullish | |
| $63.41 | $89.28 | $136.19 | +301% | Bullish | |
| $132.93 | $200.75 | $328.24 | +803% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $19.31 | $22.24 | $26.80 | +0.00% |
| August 2026 | $20.17 | $23.61 | $28.24 | +6.18% |
| September 2026 | $20.18 | $23.73 | $28.60 | +0.49% |
| October 2026 | $19.86 | $23.46 | $28.46 | -1.15% |
| November 2026 | $20.15 | $23.88 | $29.13 | +1.80% |
| December 2026 | $20.40 | $24.26 | $29.74 | +1.58% |
Click any year to see its month-by-month INVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, INVA could reach as high as $29.74, with a base case around $22.24 and support toward $19.31 — roughly 0% from $22.24. A consolidation phase looks the most probable path here.
Expect INVA to range from $20.67 to $32.22 through 2027. The $25.24 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
The INVA price prediction for 2028 points to an average of $30.89 (low $24.83, high $40.50) — a potential gain of +39% on today's $22.24. Buyers look set to stay in control over this stretch.
In 2029, INVA is projected to trade between $30.32 and $51.28, averaging $38.30 — a potential gain of +72% from today's $22.24. That is up +24% on the projected 2028 average. Momentum favours further upside here.
Innoviva, Inc.'s 2030 outlook centres on $40.27, within a $31.46 to $54.90 range. That is up +5% on the projected 2029 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, INVA could reach as high as $62.43, with a base case around $45.09 and support toward $34.79 — roughly +103% from $22.24. Momentum favours further upside here.
Expect INVA to range from $37.10 to $68.28 through 2032. The $48.62 average target implies a +119% move from current prices. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The INVA price prediction for 2033 points to an average of $49.51 (low $37.39, high $70.43) — a potential gain of +123% on today's $22.24. Momentum favours further upside here.
In 2034, INVA is projected to trade between $41.00 and $78.94, averaging $54.84 — a potential gain of +147% from today's $22.24. That is up +11% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Innoviva, Inc.'s 2035 outlook centres on $62.53, within a $46.32 to $91.02 range. That is up +14% on the projected 2034 average. That marks a +181% change versus current levels. Momentum favours further upside here.
By 2040, INVA could reach as high as $136.19, with a base case around $89.28 and support toward $63.41 — roughly +301% from $22.24. Buyers look set to stay in control over this stretch.
Expect INVA to range from $132.93 to $328.24 through 2050. The $200.75 average target implies a +803% move from current prices. That is up +125% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INVA today (≈ 44.964029 INVA) could be worth
$9,026.59
+$8,026.59 (+803%) by 2050 · US Dollar
Based on the average projected INVA price of $200.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INVAwould be worth at today's price.
$1,000 invested in INVA on Jul 10, 2025 (≈ 52.465899 INVA) would be worth
$1,166.84
+$166.84 (+16.7%) today · 1.17× · US Dollar
Based on a INVA entry price of $19.06 vs. today's $22.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22.31 | $996.86 | -0.3% |
| 1 month ago | $23 | $966.96 | -3.3% |
| 3 months ago | $23.76 | $936.03 | -6.4% |
| 6 months ago | $19.44 | $1,144.03 | +14.4% |
| 1 year ago | $19.06 | $1,166.84 | +16.7% |
| All time (5.0y) ago | $13.14 | $1,692.54 | +69.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INVA forecast.
Our base-case forecast reaches $44.00 around 2031.
Implied market cap at $44.00: $3.25B
The multi-year forecast shows rising averages and sizable ROI in later years. By 2027 the avg price is $26.32 with ROI 17.1, by 2030 the avg price is $42.62 with ROI 89.5, by 2040 the avg price is $101.62 with ROI 351.9, and by 2050 the avg price is $223.83 with ROI 895.3. The sentiment is BULLISH across most of the longer horizon (2027 onward), indicating meaningful upside potential while acknowledging the inherent uncertainty of forecasts.
Tap a question to reveal the answer.
The forecast shows an avg price of $42.62 with ROI 89.5 and bullish sentiment.
Forecasts show rising avg prices through 2050 with bullish sentiment in later years, with increasing ROI; these are estimates, not guarantees.
Yes, the forecast shows an avg price of $101.62 by 2040 (ROI 351.9) with bullish sentiment.
Current price is $22.49; 30-day range is $20.76 to $24.37.
The 2050 forecast shows an avg price of $223.83 with ROI 895.3 and bullish sentiment.
Innoviva, Inc. Community Discussion
0Share your Innoviva, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.